David Meeker will inherit CEO job at Genzyme
This article was originally published in Scrip
Sanofi has appointed David Meeker CEO of Genzyme, replacing Henri Termeer, effective 1 November 2011. He will report to Christopher Viehbacher, CEO of Sanofi and chair of Genzyme. Under Mr Meeker's leadership Genzyme plans to incorporate the rare disease business and the multiple sclerosis franchise. Mr Meeker has served at Genzyme since 1994, most recently as COO.
You may also be interested in...
Bill Sibold will take over the leadership of Sanofi's Cambridge-based Genzyme group as the unit begins the important launch of Dupixent. Meeker ends his career at Genzyme after 23 years.
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.